Cybin reports Q2 EPS ($1.39), consensus ($1.33)

“We are extremely pleased with the strong demand for our recently completed financing,” said Eric So, Interim CEO. “The participation of notable institutional investors underscores confidence in the strength of our science, the potential and differentiation of our therapeutic candidates, and our team’s proven ability to execute. This financing enables us to maintain strong momentum as we advance our Phase 2 and Phase 3 clinical trials toward key data readouts in 2026 and work to deliver meaningful clinical outcomes and potentially transformative therapies closer to patients in need. “Across the organization we are focused on a disciplined execution strategy and building a strong foundation leading up to critical clinical milestones in 2026. Our recent financing enables us to advance our late-stage programs, prepare for commercialization and retire inefficient capital structures. Coupled with our clinical progress, scientific rigor, dominant IP, measured approach to capital deployment, and leadership continuity, Cybin (CYBN) is well positioned to advance towards our upcoming data readouts and beyond.”